Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: Chronocort vs Standard Care in Congenital Adrenal Hyperplasia
NCT03532022Phase 3Withdrawn
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Planned start Oct 2018; status: withdrawn.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03532022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532022.